Target intelligence / Profile preview

Aluminum oxide (Al2O3)

Target
Al2O3
Molecular classification
Inorganic oxide, Adsorbent, Chromatographic stationary phase, Other
01

Overview

The alumina column is a fundamental component of the Molybdenum-99/Technetium-99m generator system, widely used in nuclear medicine to produce the diagnostic radioisotope Technetium-99m (StatPearls, 2023). It consists of acidic aluminum oxide (Al2O3) which serves as a chromatographic stationary phase (Wikipedia, 2024). Molybdenum-99, the parent isotope, is loaded onto the column as molybdate ions, which bind tightly to the alumina (National Academies Press, 2009). As Molybdenum-99 decays, it produces Technetium-99m in the form of pertechnetate ions. Because pertechnetate has a significantly lower affinity for the alumina than molybdate, it can be selectively eluted with a sterile saline solution for use in patient imaging (Learn Radiology Physics, 2024). This system is not a biological target but a chemical substrate for isotope separation; however, monitoring for 'aluminum breakthrough' is essential to prevent chemical impurities from interfering with subsequent radiopharmaceutical labeling or patient safety (StatPearls, 2023). The column typically contains 5 to 10 grams of acid-washed alumina to ensure efficient adsorption and elution (StatPearls, 2023). It is designed to maintain sterile and pyrogen-free conditions for the production of injectable radiopharmaceuticals (AuntMinnie, 2002).

Other names
AluminaAluminum oxide columnMo-99/Tc-99m generator columnAlumina adsorbentAcid alumina
02

Mechanism of action

The alumina column serves as a stationary phase for the chromatographic separation of radionuclides. Molybdenum-99 (as molybdate) is strongly adsorbed onto the acidic alumina, while its decay product, Technetium-99m (as pertechnetate), has a lower affinity and is eluted using a sterile saline solution.

03

Biological functions

Other
04

Disease associations

Other
05

Safety considerations

Aluminum breakthroughMolybdenum-99 breakthroughRadiolytic degradationColumn blockage
06

Interacting drugs

Molybdenum-99

1 more in the full profile.

Beyond the preview

Go deeper on Aluminum oxide (Al2O3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aluminum oxide (Al2O3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call